Ocular Therapeutix Inc. (NASDAQ: OCUL) announced that the first patient has been randomized in its HELIOS-3 Phase 3 trial for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE